1
|
Rugge M, Fassan M and Graham DY:
Epidemiology of gastric cancer. Gastric Cancer. Strong VE: Springer
International Publishing. (Cham). 23–34. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Mocellin S, Verdi D, Pooley KA and Nitti
D: Genetic variation and gastric cancer risk: A field synopsis and
meta-analysis. Gut. 64:1209–1219. 2015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Oliveira C, Pinheiro H, Figueiredo J,
Seruca R and Carneiro F: Familial gastric cancer: Genetic
susceptibility, pathology, and implications for management. Lancet
Oncol. 16:e60–e70. 2015. View Article : Google Scholar : PubMed/NCBI
|
4
|
Orditura M, Galizia G, Sforza V,
Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J,
Savastano B, Mabilia A, et al: Treatment of gastric cancer. World J
Gastroenterol. 20:1635–1649. 2014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Choi KS, Jun JK, Suh M, Park B, Noh DK,
Song SH, Jung KW, Lee HY, Choi IJ and Park EC: Effect of endoscopy
screening on stage at gastric cancer diagnosis: Results of the
National Cancer Screening Programme in Korea. Br J Cancer.
112:608–612. 2015. View Article : Google Scholar : PubMed/NCBI
|
6
|
Henriksen K, O'Bryant SE, Hampel H,
Trojanowski JQ, Montine TJ, Jeromin A, Blennow K, Lönneborg A,
Wyss-Coray T, Soares H, et al: The future of blood-based biomarkers
for Alzheimer's disease. Alzheimers Dement. 10:115–131. 2014.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Hori SS, Lutz AM, Paulmurugan R and
Gambhir SS: Correlation of plasma biomarker levels with early-stage
tumor viability in an orthotopic ovarian cancer mouse model. Clin
Cancer Res. (Suppl.):8732014.
|
8
|
Takahari D, Wakatsuki T, Mashima T,
Ichimura T, Chin K, Ogura M, Nakayama I, Matsushima T, Osumi H,
Ozaka M, et al: Plasma biomarker analysis of ramucirumab in
Japanese patients with advanced gastric cancer: Preliminary
results. J Clin Oncol. 36 (Suppl.):812018. View Article : Google Scholar
|
9
|
Perkel JM: Visiting ‘noncodarnia’.
Biotechniques. 54:301–303, 304. 2013. View Article : Google Scholar : PubMed/NCBI
|
10
|
Esteller M: Non-coding RNAs in human
disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
|
11
|
Prensner JR and Chinnaiyan AM: The
emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407.
2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Zhang K, Luo Z, Zhang Y, Zhang L, Wu L,
Liu L, Yang J, Song X and Liu J: Circulating lncRNA H19 in plasma
as a novel biomarker for breast cancer. Cancer Biomark. 17:187–194.
2016. View Article : Google Scholar : PubMed/NCBI
|
13
|
Zheng HT, Shi DB, Wang YW, Li XX, Xu Y,
Tripathi P, Gu WL, Cai GX and Cai SJ: High expression of lncRNA
MALAT1 suggests a biomarker of poor prognosis in colorectal cancer.
Int J Clin Exp Pathol. 7:31742014.PubMed/NCBI
|
14
|
Ma KX, Wang HJ, Li XR, Li T, Su G, Yang P
and Wu JW: Long noncoding RNA MALAT1 associates with the malignant
status and poor prognosis in glioma. Tumor Biol. 36:3355–3359.
2015. View Article : Google Scholar
|
15
|
Wang J, Su L, Chen X, Li P, Cai Q, Yu B,
Liu B, Wu W and Zhu Z: MALAT1 promotes cell proliferation in
gastric cancer by recruiting SF2/ASF. Biomed Pharmacother.
68:557–564. 2014. View Article : Google Scholar : PubMed/NCBI
|
16
|
Xia H, Chen Q, Chen Y, Ge X, Leng W, Tang
Q, Ren M, Chen L, Yuan D, Zhang Y, et al: The lncRNA MALAT1 is a
novel biomarker for gastric cancer metastasis. Oncotarget.
7:56209–56218. 2016. View Article : Google Scholar : PubMed/NCBI
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Li H, Yu B, Li J, Su L, Yan M, Zhu Z and
Liu B: Overexpression of lncRNA H19 enhances carcinogenesis and
metastasis of gastric cancer. Oncotarget. 5:2318–2329. 2014.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Shao Y, Chen H, Jiang X, Chen S, Li P, Ye
M, Li Q, Sun W and Guo J: Low expression of lncRNA-HMlincRNA717 in
human gastric cancer and its clinical significances. Tumor Biol.
35:9591–9595. 2014. View Article : Google Scholar
|
20
|
Thai P, Statt S, Chen CH, Liang E,
Campbell C and Wu R: Characterization of a novel long noncoding
RNA, SCAL1, induced by cigarette smoke and elevated in lung cancer
cell lines. Am J Respir Cell Mol Biol. 49:204–211. 2013. View Article : Google Scholar : PubMed/NCBI
|
21
|
Yang MH, Hu ZY, Xu C, Xie LY, Wang XY,
Chen SY and Li ZG: MALAT1 promotes colorectal cancer cell
proliferation/migration/invasion via PRKA kinase anchor protein 9.
Biochim Biophys Acta. 1852:166–174. 2015. View Article : Google Scholar : PubMed/NCBI
|
22
|
Xu S, Sui S, Zhang J, Bai N, Shi Q, Zhang
G, Gao S, You Z, Zhan C, Liu F and Pang D: Downregulation of long
noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition
via the PI3K-AKT pathway in breast cancer. Int J Clin Exp Pathol.
8:4881–4891. 2015.PubMed/NCBI
|
23
|
Kirshners A, Polaka I and Aleksejeva L:
Gastric cancer risk analysis in unhealthy habits data with
classification algorithms. Inform Technol Manag Sci. 18:97–102.
2015.
|
24
|
Hirata H, Hinoda Y, Shahryari V, Deng G,
Nakajima K, Tabatabai ZL, Ishii N and Dahiya R: Long noncoding RNA
MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and
interacts with miR-205. Cancer Res. 175:1322–1331. 2015. View Article : Google Scholar
|
25
|
Wu XS, Wang XA, Wu WG, Hu YP, Li ML, Ding
Q, Weng H, Shu YJ, Liu TY, Jiang L, et al: MALAT1 promotes the
proliferation and metastasis of gallbladder cancer cells by
activating the ERK/MAPK pathway. Cancer Biol Ther. 15:806–814.
2014. View Article : Google Scholar : PubMed/NCBI
|